PARLIAMENT QUESTION: DOMESTIC SELF-SUFFICIENCY IN CRITICAL MEDICAL RADIOISOTOPE SUPPLY

1. At a Glance

• India's medical isotope self-sufficiency hinges on the Dhruva reactor (BARC), which produces Mo-99, I-131, Lu-177 — isotopes behind ~90% of Nuclear Medicine applications [1].
• Demonstrates DAE's dual civilian role (energy + healthcare) — a recurring UPSC theme linking Science & Tech with Health governance.
• Highlights a structural demand-supply gap, met partly via imports — tests understanding of strategic self-reliance vs. dependency in critical technology sectors.
• Institutional linkage: BARC (production) → BRIT (distribution) → hospitals — a supply chain UPSC often probes for "implementing agency" traps.

2. Why in the News

• Answered in Parliament on 12 Aug 2026 via PIB press release, giving five-year (2021-22 to 2025-26) production data for Mo-99, I-131, Lu-177 from Dhruva [1].
• Follows an earlier Parliament Question (PRID=2153081) on the shortage of medical radioisotopes, flagging gaps for Mo-99 and I-131, and a 10-15% shortfall in Lu-177 [2].

3. Background & Evolution

• Reactor-produced medical radioisotopes have historically been supplied through Dhruva reactor, BARC, on a weekly/fortnightly cycle owing to short half-lives [1].
• Board of Radiation and Isotope Technology (BRIT), a DAE constituent unit, is the statutory distribution arm supplying radiopharmaceuticals to hospitals for cancer diagnosis/therapy [1][2].
• Recognizing persistent supply gaps, BARC obtained in-principle approval for a PPP-based new Isotope Production Reactor, targeted to start production around 2035 with a 0.5 million Curie (MCi) capacity — a major capacity leap from Dhruva's current ~50 Ci/week-batch levels [2].
• Parallelly, Tata Memorial Centre has expanded nuclear medicine access to Tier-2 cities (Chandigarh, Visakhapatnam, Bhubaneswar, Guwahati, Varanasi, Muzaffarpur) and Tier-3 Sangrur [2].

4. Core Static Facts

Parameter	Detail
Key isotopes	Mo-99 (via Mo-99m/Tc-99m), I-131, Lu-177 [1]
Share of Nuclear Medicine applications	~90% [1]
Production site	Dhruva reactor, BARC, Mumbai [1]
Production capacity	Lu-177: 50 Ci/batch; Mo-99: 50 Ci/week; I-131: 50 Ci/week [1]
Nodal parent department	Department of Atomic Energy (DAE) [1]
Distribution agency	Board of Radiation and Isotope Technology (BRIT) [1][2]
Lu-177 production (Ci), 2021-22 to 2025-26	473, 532, 684, 681, 976 [1]
Mo-99 production (Ci), 2021-22 to 2025-26	662, 693, 268, 283, 550 [1]
I-131 production (Ci), 2021-22 to 2025-26	749, 813, 710, 623, 770 [1]
Import sources (during shortfalls)	Russia, Belgium, Australia, Egypt, Poland, South Africa [1]
2025-26 imports	Lu-177: 136 Ci; Mo-99: 516 Ci; I-131: 421 Ci [1]
Future capacity project	New Isotope Production Reactor (PPP model), ~2035, 0.5 MCi capacity [2]
F-18 constraint	Half-life 110 minutes limits distribution radius [2]

5. Multi-Dimensional Analysis

Scientific/Technological

• Reflects India's indigenous reactor-based (not cyclotron/accelerator-based, barring F-18) radioisotope production model, contrasting with countries relying on dedicated isotope-production reactors [1][2].
• The proposed 0.5 MCi PPP reactor signals a shift toward private-sector participation in a traditionally state-monopoly nuclear domain [2].

Administrative

• Weekly/fortnightly production cycles constrained by short isotope half-lives create logistical bottlenecks in hospital supply chains [1].
• BRIT meets roughly 85-90% of confirmed domestic orders in normal operations, with shortfalls linked to Dhruva's reactor maintenance/technical shutdowns [1][2].

Economic

• Import dependency (Russia, Belgium, Australia, Egypt, Poland, South Africa) imposes forex and supply-chain vulnerability costs on India's cancer-care ecosystem [1].
• PPP financing model for the new reactor indicates a cost-sharing strategy to scale capacity without full central capex burden [2].

Social

• Direct bearing on cancer diagnosis and therapy access; geographic expansion (Tata Memorial Centre) to Tier-2/3 cities aims to reduce urban-rural healthcare access disparity [2].
• Gaps in Mo-99/I-131 supply can disrupt time-sensitive diagnostic and therapeutic nuclear medicine procedures nationwide [2].

Governance

• Demonstrates Parliament's oversight role via Question Hour in surfacing production/import data transparency for a strategic health-security sector [1][2].

6. Recent Developments (last 12-18 months)

• 12 Aug 2026: PIB release gives 5-year production figures (2021-26) for Mo-99, I-131, Lu-177 and notes rising Lu-177 output (976 Ci in 2025-26, highest in the series) [1].
• 2025-26: Substantial imports recorded — Mo-99 (516 Ci), I-131 (421 Ci), Lu-177 (136 Ci) — to bridge domestic shortfalls [1].
• Earlier Parliament Question (PRID 2153081) flagged persistent shortage concerns and confirmed BARC's PPP isotope reactor is targeted for ~2035 [2].

7. Prelims Hooks

• Mo-99, I-131, and Lu-177 together account for ~90% of Nuclear Medicine applications in India [1].
• These isotopes are produced at the Dhruva reactor, BARC — not at a cyclotron [1].
• Production capacity benchmark: 50 Ci/week (or batch) for each of the three isotopes [1].
• Distribution agency: Board of Radiation and Isotope Technology (BRIT), a DAE constituent unit — not ICMR or Ministry of Health [1][2].
• 2025-26 Lu-177 production peaked at 976 Ci, the highest in the 2021-26 dataset [1].
• Mo-99 production dipped sharply in 2023-24 (268 Ci) from 693 Ci the previous year [1].
• India imports shortfall isotopes from Russia, Belgium, Australia, Egypt, Poland, South Africa [1].
• Proposed new Isotope Production Reactor targets 0.5 million Curie (MCi) capacity, expected around 2035 [2].
• The new reactor is being developed under a Public-Private Partnership (PPP) model [2].
• Fluorine-18 (F-18), produced via medical cyclotron (not Dhruva), has a short half-life of 110 minutes, restricting distribution range [2].
• Tata Memorial Centre expanded nuclear medicine services to Tier-2 cities: Chandigarh, Visakhapatnam, Bhubaneswar, Guwahati, Varanasi, Muzaffarpur, and Tier-3 city Sangrur [2].
• Parent department for all these initiatives: Department of Atomic Energy (DAE) [1][2].
• BRIT meets approximately 85-90% of confirmed domestic orders under normal operating conditions [2].

8. Mains Relevance

• GS-III: Science & Technology — developments in space, nuclear science; also indigenization of technology; Health infrastructure.
• GS-II: Government policies/interventions for development in the health sector; issues relating to access to healthcare.
• Possible question stems: 1. "Discuss India's self-sufficiency status in critical medical radioisotope production. What structural constraints limit domestic supply, and how does the proposed PPP-based Isotope Production Reactor address them?" 2. "Examine the institutional architecture (BARC-BRIT-DAE) governing nuclear medicine supply in India. What are the implications of import dependency on isotopes like Mo-99 for healthcare security?" 3. "Nuclear technology has significant civilian applications beyond power generation. Discuss with reference to medical radioisotope production in India."

9. Related Topics to Study Next

• Department of Atomic Energy (DAE) — structure and constituent units — parent body governing BARC, BRIT, NPCIL; frequently tested for "which agency does what."
• Dhruva and other research reactors (CIRUS, Apsara) — comparative reactor roles (research vs. power vs. isotope production).
• PPP models in strategic/nuclear sectors — link to the 2015 amendment allowing private participation in nuclear power generation.
• National Cancer Grid / Tata Memorial Centre expansion — healthcare access and Tier-2/3 city infrastructure schemes.
• Ayushman Bharat Health Infrastructure Mission — broader health infrastructure decentralization context.
• India's civil nuclear cooperation agreements (with Russia, etc.) — relevant to import sourcing of isotopes and broader nuclear diplomacy.
• Make in India / Atmanirbhar Bharat in strategic sectors — self-reliance framing applicable to critical medical technologies.

10. Common Errors / Trap Areas

• Confusing BRIT (distribution/production support) with AERB (Atomic Energy Regulatory Board, a safety regulator) — different mandates, both under DAE.
• Assuming all isotopes are Dhruva-produced — F-18 is cyclotron-produced, not reactor-produced [2].
• Mixing up production capacity (50 Ci/week benchmark) with actual production data, which fluctuated below capacity in several years (e.g., Mo-99 at 268 Ci in 2023-24 vs. theoretical ~2600 Ci/year capacity) [1].
• Assigning this topic to Ministry of Health & Family Welfare — the correct nodal ministry/department is DAE, not MoHFW.
• Treating the 2035 PPP reactor project as already operational — it is still at the in-principle approval / planning stage [2].